Which of the following statements is true of pramlintide (Symlin) ?
A) It is an oral dipeptidyl-peptidase-4 (DPP-4) inhibitor.
B) Use leads to decreased caloric intake and potential weight loss.
C) It is approved for type I diabetes as an adjunct treatment in patients who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy.
D) Both a and b are true.
E) Both b and c are true.
Correct Answer:
Verified
Q7: Insulin is usually administered
A)orally.
B)by subcutaneous injection.
C)by intramuscular
Q24: Acarbose lowers blood glucose by
A)slowing glucose absorption.
B)enhancing
Q28: The hemoglobin A1C level should be more
Q29: Which oral antidiabetic agent requires administration for
Q32: Insulin is a pancreatic hormone that promotes
Q34: Exenatide (Byetta)is the first of a new
Q35: The glycosylated hemoglobin test more accurately measures
Q37: More people are diagnosed with type II
Q39: The U.S.Food and Drug Administration (FDA)recommends checking
Q41: Acarbose (Precose)slows the breakdown of ingested carbohydrates
Unlock this Answer For Free Now!
View this answer and more for free by performing one of the following actions
Scan the QR code to install the App and get 2 free unlocks
Unlock quizzes for free by uploading documents